The American drug authority FDA has given a special classification to the drug candidate exidavnemab from Swedish Bioarctic, according to a press release from the pharmaceutical company.
The classification concerns the treatment of multiple system atrophy (MSA). It is a rare but deadly disease that affects the central and autonomic nervous system. Today, there is no cure for the disease and no treatment to slow it down.
The FDA grants so-called orphan drug status to products intended for the treatment of diseases that affect fewer than 200,000 people in the USA.
The status is intended, among other things, to encourage the development of medicines for rare diseases with significant medical needs through tax deductions and regulatory exemptions.
